3 results
The primary objective of this randomized controlled clinical study is to evaluate the peri-procedural safety and potential effectiveness (mechanistic effect) of implanting the IASD System II in heart failure patients with an LV ejection fraction…
The primary objective of this study is to assess the efficacy of Triumeq versus placebo on overall survival, defined as death from any cause, in participants with ALS at 24 months or after a minimum of 212 events.
The primary objective of this randomized controlled clinical trial is to evaluate the clinical efficacy and safety of the IASD System II in symptomatic heart failure patients with an LV ejection fraction >=40%, and elevated left sided filling…